Dotmatics
  • Platform

    Scientific Intelligence Platform

    AI-powered data management and workflow automation for multimodal scientific discovery

    Learn More

    Capabilities

    Adaptive Workflows

    Customize, automate, and scale your lab workflows

    Artificial Intelligence

    Leverage AI and ML to accurately predict scientific outcomes

    Material & Ontology Management

    Classify materials and manage entities with full traceability

    Luma Products

    Geneious Luma

    Accelerated antibody discovery for sequence analysis, construct design, and lab execution—integrating the power of Geneious Prime and Geneious Biologics with Luma’s adaptive workflows.

    Lab Connect

    Automated lab data ingestion and modeling—connect instruments, structure scientific data, and streamline lab operations with seamless integration.

  • Solutions

    The State of Chemicals & Materials

    Uncover key trends shaping the chemicals and materials industry

    Read More

    Solutions

    Antibody & Protein Engineering

    Integrated registration, lab workflow and data management

    Flow Cytometry

    Automated flow data processing and auto-gating

    Industry

    Biology Discovery

    Chemistry R&D

    Chemicals and Materials

  • Products

    R&D Software for Scientists

    Review our comprehensive portfolio of products driving scientific breakthroughs for R&D innovation and collaboration.

    Explore All

    BIOINFORMATICS

    SnapGene

    Geneious Prime

    Geneious Biologics

    CHEMINFORMATICS

    Vortex

    DATA ANALYSIS & VISUALIZATION

    Prism

    ELN

    ELN & Data Discovery Platform

    FLOW CYTOMETRY

    OMIQ

    FCS Express

    MULTIMODAL SCIENCE

    Scientific Intelligence Platform

    PROTEOMICS

    Protein Metrics

  • Resources

    Watch a Demo

    See Dotmatics in action with on-demand product tours and demos.

    View Demos

    Resources

    All Resources

    Explore the resource library

    Blog

    Latest insights and perspectives to lead your R&D

    Case Studies

    How our customers are using Dotmatics

    Ebooks & White Papers

    News and discoveries from industry leaders

    Videos

    On-demand videos from industry topics to product demos

    Events

    Dotmatics Summit

    Upcoming Events & Webinars

  • Company

    COMPANY

    About Us

    Careers

    Contact Us

    COMPANY

    News & Media

    Partners

    Portfolio

    Latest News

Request Demo
Dotmatics
Request Demo
  • Platform

    Scientific Intelligence Platform

    AI-powered data management and workflow automation for multimodal scientific discovery

    Learn More

    Capabilities

    Adaptive Workflows

    Customize, automate, and scale your lab workflows

    Artificial Intelligence

    Leverage AI and ML to accurately predict scientific outcomes

    Material & Ontology Management

    Classify materials and manage entities with full traceability

    Luma Products

    Geneious Luma

    Accelerated antibody discovery for sequence analysis, construct design, and lab execution—integrating the power of Geneious Prime and Geneious Biologics with Luma’s adaptive workflows.

    Lab Connect

    Automated lab data ingestion and modeling—connect instruments, structure scientific data, and streamline lab operations with seamless integration.

  • Solutions

    The State of Chemicals & Materials

    Uncover key trends shaping the chemicals and materials industry

    Read More

    Solutions

    Antibody & Protein Engineering

    Integrated registration, lab workflow and data management

    Flow Cytometry

    Automated flow data processing and auto-gating

    Industry

    Biology Discovery

    Chemistry R&D

    Chemicals and Materials

  • Products

    R&D Software for Scientists

    Review our comprehensive portfolio of products driving scientific breakthroughs for R&D innovation and collaboration.

    Explore All

    BIOINFORMATICS

    SnapGene

    Geneious Prime

    Geneious Biologics

    CHEMINFORMATICS

    Vortex

    DATA ANALYSIS & VISUALIZATION

    Prism

    ELN

    ELN & Data Discovery Platform

    FLOW CYTOMETRY

    OMIQ

    FCS Express

    MULTIMODAL SCIENCE

    Scientific Intelligence Platform

    PROTEOMICS

    Protein Metrics

  • Resources

    Watch a Demo

    See Dotmatics in action with on-demand product tours and demos.

    View Demos

    Resources

    All Resources

    Explore the resource library

    Blog

    Latest insights and perspectives to lead your R&D

    Case Studies

    How our customers are using Dotmatics

    Ebooks & White Papers

    News and discoveries from industry leaders

    Videos

    On-demand videos from industry topics to product demos

    Events

    Dotmatics Summit

    Upcoming Events & Webinars

  • Company

    COMPANY

    About Us

    Careers

    Contact Us

    COMPANY

    News & Media

    Partners

    Portfolio

    Latest News

The Pursuit of Follow-on Biologics, Biosimilars, and Biobetters

Latest Blogs
Case Studies
White Papers
Upcoming Events
News
Search

The pursuit of follow-on biologics is quite different than developing generic small molecule drugs, and companies must position themselves to make the most of their data and time in this endeavor.

In the realm of small molecule drugs, generic competition is well established and straight forward. Manufacturing processes are standardized, and generics are essentially chemical equivalents to their originals, with only slight ingredient variation allowed. Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products; they are often readily substitutable for their primary counterparts at the pharmacy and are priced around 80-85% less.

It is different with biologics.

biosimilars follow on biologics

Creating Equivalent Biologics Presents Greater Complexities

Greater complexity begets greater challenges.

Biologics are more complex—not only in their larger structures, but also in the complicated processes used to analyze and develop them. In fact, the term ‘generic’ is not even used for biologics; instead, we have ‘biosimilars’ or ‘biobetters,’ which each have their own pros and cons.[1]

Biosimilars

Biosimilars, while not identical to their reference structures, undergo thorough testing to establish similarity in terms of structure, function, efficacy, and safety. Like generic small molecule drugs, biosimilars benefit from an abbreviated approval process with less stringent clinical trial requirements; however, approval is only possible after a reference drug’s exclusivity expires, and companies must provide sufficient evidence that a biosimilar product should be granted the same indication(s) as its reference product. Currently, over thirty wide-ranging biosimilar products are approved in the United States and that number is expected to grow as patents from the earliest biologics expire.

While the time and cost to develop biosimilars are lower than for their reference biologics, the differences are not as vast as with small molecule generics; a key reason for this is because while reference biologic structures are known, the intricate processes used to develop those structures remain proprietary. As a result, patients see only 15% to 35% price reductions with biosimilars. Additionally, in the US, the FDA must declare biosimilar drugs interchangeable for them to be readily substituted for their reference drugs without a change in prescription. While this presents yet another hurdle to developers, it also comes with a period of exclusivity that prevents other biosimilars from too quickly receiving the same clearance.

Biobetters

Biobetters try to improve upon reference biologics, not just emulate them. They are currently considered new drugs and therefore receive patent exclusivity. While this means no fast-tracked approval process, it also means developers can avoid waiting for the reference drug’s patent expiration, making it possible for a biobetter to beat a biosimilar to market.

Biobetters are subject to all the rigorous testing and trials required for a new drug. However, developers have a head-start, having a known target protein and established efficacy and safety data for the reference structure. This knowledge can be used explore things like structural changes, chemical modifications, or process alterations that could help deliver an alternative that is hopefully more efficacious, better tolerated, safer, easier to administer, or longer-lasting than the original.

Facilitating the Pursuit of Biosimilars and Biobetters

In the pursuit of biosimilars and biobetters, data are key. Researchers need to not only leverage scores of data related to a reference biologic, but they must also consider that data in relation to the volumes of data coming from their study of new candidates’ pharmacokinetics, pharmacodynamics, safety, purity, potency, immunogenicity, and, ultimately, clinical response.

Dotmatics can help by providing a united scientific research informatics platform that delivers:

  • unparalleled data management and collaboration capabilities

  • deep and broad scientific capabilities to support CAR-T therapy, RNA therapy, and antibody discovery research

  • trusted bioinformatics and molecular biology applications, including Geneious, SnapGene, Protein Metrics, and Prism

Learn More

Request a demo of Dotmatics to learn how we can help you expedite biosimilar and biobetter research by providing solutions that capture data across teams and disciplines, reduce operational inefficiencies, and inform critical decisions.

References

[1]: McNeely, Wendy. “Biosimilar vs Biobetter – a two-horse race. A white paper.”
Adis Business Intelligence (part of Springer Nature).
https://media.springernature.com/full/springer-cms/rest/v1/content/15588272/data/v4

Get the latest science news in your inbox.

Dotmatics Logo
Footer Icon 1Footer Icon 2Footer Icon 3
Request Demo
Get Support
Luma Scientific Intelligence Platform
Luma Overview
Instrument & Data Integration
Artificial Intelligence
Solutions
Antibody and Protein Engineering
Flow Cytometry
Biologics Discovery
Chemicals & Materials
Small Molecule Discovery
Resources
All resources
Blog
Case Studies
Demos
White Papers
Webinars
What’s New
Upcoming Events
FAQ
Explore
FAIR Data Principles
Lab workflow management
Lab Data Automation for Life Sciences
Lab Data Automation for Chemicals & Materials
Lab Data Informatics for Drug Discovery
Modern ELN
Products
All Dotmatics Products
Dotmatics ELN & Data Discovery
EasyPanel
FCS Express
Geneious Biologics
Geneious Prime
GraphPad Prism
LabArchives
M-Star
nQuery
OMIQ
Protein Metrics
SnapGene
SoftGenetics
Vortex
Virscidian
Company
About Us
Careers
Contact Us
News & Media
Partners
Footer Icon 1Footer Icon 2Footer Icon 3
Request Demo
Get Support
Do Not Sell or Share My Personal Information
UK Modern Slavery Act
Privacy Policy
Terms & Conditions
Trademarks